New clinical data highlight improved disease control, reduced eye bulging, and weight-loss benefits, potentially broadening options for patients with unmet needs.
|Articles|December 1, 2012
- BioPharm International-12-01-2012
- Volume 25
- Issue 12
BioPharm International, December 2012 Issue (PDF)
Job Security in a Changing BioPharma Environment
Advertisement
Articles in this issue
almost 14 years ago
Bioanalytical Methods for Sample Cleanupalmost 14 years ago
Report from South Koreaalmost 14 years ago
When Disaster Strikes at Homealmost 14 years ago
Research Policies Pose New Challenge for US Administrationalmost 14 years ago
Patents and Postapproval Batch Testingalmost 14 years ago
Navigating Emerging Marketsalmost 14 years ago
Discovery Pipeline: Understanding Cellular Reprogrammingalmost 14 years ago
Glycan Analysis: A PrimerAdvertisement
Related to this article
Antisense oligonucleotides are reshaping drug design, from RNase H gapmers to inhaled delivery; this FAQ explains how they work and why trials still fail.
Bristol Myers Squibb's Nathan Pennell explains how the MRD endpoint supports accelerated approval in multiple myeloma without changing how clinicians monitor patients.
Once-weekly amylin analog petrelintide produced up to 9.2% weight loss at 28 weeks in adults with obesity and type 2 diabetes, Zealand Pharma reports.
Teprotumumab N01 (Sycume) reduced eye bulging in 60.4% of patients with chronic, inactive thyroid eye disease in a phase 3 trial.
Tecentriq plus chemotherapy gains FDA approval for stage III dMMR colon cancer after a phase 3 trial showed improved disease-free survival.
New clinical milestones, manufacturing investments, and regulatory incentives could help developers overcome barriers to delivering treatments for patients with rare diseases.
Genglycos, the gene therapy that earned the voucher, will fund new Ultragenyx therapies for other rare and ultra-rare diseases.
Advertisement
Advertisement